Fig. 6.

Creb1 transcription factor improves the blood flow recovery after hindlimb ischemia. a Gastrocnemius muscle was isolated from control and ischemic legs of both WT and Mapk10^−/− mice on day 3 after femoral artery ligation and immunoblot analysis was performed with antibodies for pCreb1 (phosphor-Ser133), Creb1, and GAPDH. b Lysates prepared from N2a cells treated with control siRNA or siRNA against Mapk10 (48 h) were examined by immunoblot analysis using antibodies for Creb1 and GAPDH. c A Luciferase reporter assay for the Creb1 recombinase enzyme was performed on N2a cells treated with either control siRNA or Mapk10 siRNA (48 h) both with and without Forskolin (30 min) a Creb1 activator (n = 4 in each group). d Control Ad-GFP and Ad-Creb1 were injected (single dose of 2 × 10⁸ c.f.u.) into the gastrocnemius muscle of WT mice. Three days following the injection femoral artery ligation was performed and blood flow measurements by Laser Speckle Contrast Imager (n = 7 in each group) were obtained. e Representative images of hindlimb blood flow of WT mice 7 days post femoral artery ligation and adenoviral (control Ad-GFP and Ad-Creb1) injection were measured by laser speckle contrast imaging. f RNA was prepared from control and Creb1 siRNA-treated neuro-2a cell line with hypoxia for 90 min and qRT-PCR was performed for genes indicated (n = 4 in each group). g RNA was isolated from control and Creb1 overexpressing N2a cells and qRT-PCR was performed for growth factors related genes (n = 5 in each group). Statistically significant differences between groups are indicated (*P < 0.05 by Student’s t test). The data are mean ± SEM. Source data are provided as a Source Data file